Additionally, two other biologics, ixekizumab (anti-IL17A)10, 11 and brodalumab (an antibody to the IL-17 receptor, IL-17RA)12, 13, have shown efficacy in psoriasis in late stage clinical trials. Here, IL17A is linked to psoriasis.